gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · ARDXHealthcarePharmaceuticals

Ardelyx, Inc. (ARDX)

$3.09−5.50%
Close Oct 16, 2026 · split-adjusted
Oct 16, 2026$3.09▼ 38.81% in range
Oct 16, 2025Low $3.09 · High $7.99Oct 16, 2026
What changed · written from our data
As of Oct 16, 2026

Ardelyx closed at $3.09 on Oct 16, down 5.50%, within 0.0% of its 52-week closing low. Volume of 5.8M shares was 1.28× its 20-day average (above normal).

Split-adjusted performance: -8.6% over one month, -52.1% over six months, -39.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $120.88M, up 23.8% from a year earlier, with a net margin of -13.8%.

Short interest was 27.7M shares at the Sep 30 settlement, up 8.1% from the prior report (11.4% of float, 6.6 days to cover).

Market cap$797.8M258.2M shares
Revenue · quarter$120.9M+23.8% YoY
Diluted EPS$-0.07—
P/E · TTM—P/S 1.8×
Net margin-13.8%Gross 95.2%
Dividend yieldNone
52-week range3.09 – 7.99−61.3% from high
Volume5.8M1.28× 20-day avg
Volatility · 60d49.7%Annualised
Short % of float11.4%6.6 days to cover
Net cash$30.0MCash $281.8M
Next earnings—Not scheduled
Split-adjusted performance
1W −5.8%1M −8.6%3M −39.3%6M −52.1%YTD −47.0%1Y −39.8%3Y −12.7%5Y +147.2%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 422 companies (100 = best)

6-month momentum24
Revenue growth67
Net margin62
Value (low P/E)—
Size67

Industry medians: 6-month return −26.8%, revenue growth +6.4%, net margin −39.7%, P/E 15.8×.

Short interest

Details →
Shares short27.7M+8.1% vs prior
Days to cover6.6Settled Sep 30
% of float11.4%
Short vol. 10d55.5%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
ARDXArdelyx$3.09−5.50%−52.1%+23.8%−13.8%—$797.8M
CRVSCorvus Pharmaceuticals$9.52−3.35%−43.1%———$800.8MCompare
ALMSAlumis$6.12−3.01%−75.5%−37.7%−8557.2%—$792.1MCompare
KURAKura Oncology$9.08−6.39%−6.2%+36.5%−327.3%—$807.8MCompare
VSTMVerastem$8.65−6.28%+31.5%+1775.4%−86.5%—$783.4MCompare
MLTXMoonLake Immunotherapeutics$9.55−6.92%−47.9%———$812.8MCompare
AVBPArriVent BioPharma$16.66−0.77%−43.8%———$821.5MCompare
ABUSArbutus Biopharma$4.22−1.63%−10.6%−90.6%−512.0%5.5$836.0MCompare
AKTSAktis Oncology$15.06−5.93%−25.6%—−713.5%—$837.6MCompare

News about Ardelyx

All news →
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS LawGlobeNewswire Inc. · 1d ago▼ NegativeBronstein, Gewirtz & Grossman LLC Urges Ardelyx, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc. · 2d ago▼ NegativeROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDXGlobeNewswire Inc. · 3d ago▼ NegativeROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDXGlobeNewswire Inc. · 6d ago▼ NegativeROSEN, LEADING TRIAL ATTORNEYS, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDXGlobeNewswire Inc. · Oct 9, 2026▼ Negative

Quick answers

What does Ardelyx do?
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines.
What is ARDX's market cap?
$797.80M, based on the Oct 16 close of $3.09.
Does Ardelyx pay a dividend?
No regular cash dividend has been paid in the last year.
How much of ARDX is sold short?
27.7M shares, 11.4% of float, as of Sep 30, 2026.
What sector is ARDX in?
Healthcare, in the Pharmaceuticals industry.

About Ardelyx

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

HQ: Fremont, CA489 employeesListed Jun 19, 2014ardelyx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology